Duchenne Muscular Dystrophy Market Outlook 2034: EMA, PDMA, FDA Approval, Competitive Landscape, Clinical Trials, Therapies, and Companies by DelveInsight

Duchenne Muscular Dystrophy Market

The Duchenne Muscular Dystrophy (DMD) market in the 7MM reached approximately USD 2.15 billion in 2023 and is expected to grow significantly due to increased drug uptake, rising awareness, and the anticipated launch of one-time gene therapies. Current treatment approaches focus on gene replacement, dystrophin restoration, membrane stabilization, and inflammation reduction.

In the US, approved therapies include EMFLAZA, VYONDYS 53, EXONDYS 51, AMONDYS 45, VILTEPSO, and the gene therapy ELEVIDYS, although its full approval remains under review. In early 2024, Santhera introduced AGAMREE in Germany, marking its commercial debut.

Across EU4 and the UK, steroid treatments and TRANSLARNA dominate, while Japan relies on VILTEPSO. Future launches from companies such as Santhera/ReveraGen, Taiho, FibroGen, Capricor, Italfarmaco, Antisense Therapeutics, and Sarepta are expected to expand the market further, driven by increasing disease prevalence and broader therapeutic availability worldwide.

DelveInsight’s “Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast–2034” report provides a comprehensive analysis of Duchenne Muscular Dystrophy, including detailed historical and projected epidemiology, along with evolving market trends across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

The Duchenne Muscular Dystrophy market is anticipated to grow substantially throughout the forecast period, driven by rising disease prevalence and improved awareness. Additionally, the introduction of emerging, multi-stage pipeline therapies is expected to transform market dynamics and fuel further expansion.

To Know in detail about the Duchenne Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Duchenne Muscular Dystrophy Market Outlook

Some of the key facts of the Duchenne Muscular Dystrophy Market Report:

• The Duchenne Muscular Dystrophy market size was valued approximately USD 2,150 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In December 2025, Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel, the Company’s investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD).
• In September 2025, sDyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug designation for DYNE-251 in individuals with Duchenne muscular dystrophy (DMD) who have mutations in the DMD gene that are amenable to exon 51 skipping. DYNE-251 is being evaluated in the ongoing Phase 1/2 DELIVER global clinical trial.
• In June 2025, Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company committed to developing new products for rare diseases, shared the latest positive results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the annual Parent Project Muscular Dystrophy (PPMD) conference in Las Vegas. These new results highlight multiple indicators of cardiac benefit with ifetroban treatment in DMD heart disease, the leading cause of death in DMD, including previously unreported pharmacokinetic findings and cardiac biomarker data that demonstrate the drug’s potential to prevent ongoing heart damage.
• In March 2025, Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced the U.S. Food and Drug Administration (“FDA”) has accepted for review its Biologics License Application (“BLA”) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (“DMD”) cardiomyopathy. Additionally, the FDA granted the BLA Priority Review with a Prescription Drug User Fee Act (“PDUFA”) target action date of August 31, 2025 and at this time, the FDA has not identified any potential review issues.
• In March 2025, Italfarmaco S.p.A. today announced a comprehensive update on the regulatory and clinical advancements for givinostat, the company’s drug for the treatment of Duchenne muscular dystrophy (DMD). The update highlights key regulatory milestones and ongoing clinical trials.
• In November 2024, Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Cumberland is completing the FIGHT DMD™ trial, a multicenter, double-blind, placebo-controlled Phase II study investigating the pharmacokinetics, safety and efficacy of once daily oral Ifetroban in patients with DMD. Results will be announced later this year.
• In January 2024, Santhera Pharmaceuticals initiated the availability of AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) patients aged four years and older in Germany. This marks a significant milestone as Santhera Pharmaceuticals transitions into the “commercial stage” of its biopharmaceutical journey through the official launch of this medication in Germany.
• In 2023, the United States reported approximately 17,000 total prevalent cases of Duchenne muscular dystrophy (DMM). The majority of cases were observed in children aged 5-9 years. It is anticipated that these numbers will increase by the year 2034.
• In 2023, the United States had the highest number of prevalent cases of Duchenne muscular dystrophy (DMM) among the 7MM countries, totaling approximately 17,200 cases. This figure is projected to rise at a respectable compound annual growth rate (CAGR).
• In the United States in 2023, there were approximately 13,800 cases of large mutation, around 3,400 cases of small mutation, and roughly 1,700 cases of point mutation. It is anticipated that as prevalence rates rise, these numbers will also increase during the study period from 2024 to 2034.
• In the EU4 countries (Germany, France, Italy, and Spain) along with the United Kingdom, the highest prevalence of Duchenne Muscular Dystrophy (DMD) was observed in the UK, totaling approximately 3,000 cases in 2022. This was followed by Germany and France, whereas Spain had the lowest number of cases recorded in the same year.
• In the present US market, there are several approved products—EMFLAZA (deflazacort), VYONDYS 53 (golodirsen), EXONDYS 51 (eteplirsen), AMONDYS 45 (casimersen), and VILTEPSO (viltolarsen)—available for individuals with Duchenne Muscular Dystrophy (DMD). Within the EU4 countries and the UK, steroid therapies dominate the current market, accompanied by an approved medication designed for DMD patients with the nonsense mutation, TRANSLARNA (ataluren). However, in Japan, the sole approved treatment available is VILTEPSO (viltolarsen).
• Key Duchenne Muscular Dystrophy Companies: Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others
• Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others
• The Duchenne Muscular Dystrophy epidemiology based on gender analyzed that Duchenne Muscular Dystrophy rarely affects females
• In 2023, the age group with the highest number of cases was 5-9, totaling approximately 5,700 cases, followed by the 10-14 age group with around 5,000 cases. Duchenne muscular dystrophy (DMD) is uncommon in individuals above the age of 30.
• The Duchenne Muscular Dystrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.

Request for Free Sample Report for Latest Duchenne Muscular Dystrophy Statistics: Duchenne Muscular Dystrophy Treatment Market

Duchenne Muscular Dystrophy Overview Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects males, typically becoming apparent in early childhood, around ages 3 to 5. Duchenne Muscular Dystrophy is caused by mutations in the dystrophin gene, which leads to the absence or dysfunction of the dystrophin protein crucial for maintaining muscle integrity. Symptoms include muscle weakness, difficulty walking, frequent falls, and eventually, difficulty with breathing and heart function.

Duchenne Muscular Dystrophy Diagnosis often involves genetic testing and muscle biopsy. While there is no cure for Duchenne Muscular Dystrophy, various interventions aim to manage symptoms, slow disease progression, and improve quality of life. This may include physical therapy, orthopedic interventions like braces or surgery, respiratory support, and medications like corticosteroids. Emerging therapies such as gene therapy and exon skipping hold promise for future treatments.

Duchenne Muscular Dystrophy has a progressive course, with most individuals losing the ability to walk by their early teens and experiencing life-threatening complications in adulthood. However, advancements in care and management have extended life expectancy and improved outcomes for many individuals with Duchenne Muscular Dystrophy, emphasizing the importance of comprehensive multidisciplinary care and support for patients and their families.

Get a Free sample for the Duchenne Muscular Dystrophy Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr

Duchenne Muscular Dystrophy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Duchenne Muscular Dystrophy Epidemiology Segmentation:

The Duchenne Muscular Dystrophy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Duchenne Muscular Dystrophy
• Prevalent Cases of Duchenne Muscular Dystrophy by severity
• Gender-specific Prevalence of Duchenne Muscular Dystrophy
• Diagnosed Cases of Episodic and Chronic Duchenne Muscular Dystrophy

Download the report to understand which factors are driving Duchenne Muscular Dystrophy epidemiology trends @ Duchenne Muscular Dystrophy Patient Pool Forecasting

Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Duchenne Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Duchenne Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Duchenne Muscular Dystrophy Therapies and Key Companies

• Givinostat (ITF2357): Italfarmaco
• ATL1102: Antisense Therapeutics
• SRP-9001: Sarepta Therapeutics
• Vamorolone: Santhera Pharmaceuticals/ReveraGen Biopharma
• PF06939926: Pfizer
• Pamrevlumab: FibroGen
• CAP-1002: Capricor Therapeutics
• Pamrevlumab: Fibrogen
• Delandistrogene moxeparvovec: Roche/Sarepta Therapeutics
• EDG 5506: Edgewise Therapeutics
• WVE N531: Wave Life Sciences Ltd
• PGN EDO51: PepGen
• UX810: Ultragenyx Pharmaceutical

Request for Sample Report @ Duchenne Muscular Dystrophy Companies and FDA Approvalss

Duchenne Muscular Dystrophy Market Strengths

• The pipeline of DMD is robust with the advent of several potential products in late-stage of clinical development.
• Several new therapies have been approved for the treatment of DMD recently, even Japan has witnessed the launch of VILTEPSO now.

Duchenne Muscular Dystrophy Market Opportunities

Wider commercial opportunity for therapies such as Capricor’s CAP-1002 and Antisense’s ATL1102, which are specifically focusing on improving upper limb functions in DMD patients and are targeting a much larger patient segment when compared to the Exon-Skipping therapies.

Scope of the Duchenne Muscular Dystrophy Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Duchenne Muscular Dystrophy Companies: Capricor Therapeutics (NASDAQ: CAPR), Santhera Pharmaceuticals (SWX: SANN), ReveraGen Biopharma (Private), Edgewise Therapeutics (NASDAQ: EWTX), FibroGen (NASDAQ: FGEN), Roche (SWX: ROG), Pfizer (NYSE: PFE), Sarepta Therapeutics (NASDAQ: SRPT), Antisense Therapeutics (ASX: ANP), Italfarmaco (Private), and others
• Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others
• Duchenne Muscular Dystrophy Therapeutic Assessment: Duchenne Muscular Dystrophy current marketed and Duchenne Muscular Dystrophy emerging therapies
• Duchenne Muscular Dystrophy Market Dynamics: Duchenne Muscular Dystrophy market drivers and Duchenne Muscular Dystrophy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Duchenne Muscular Dystrophy Unmet Needs, KOL’s views, Analyst’s views, Duchenne Muscular Dystrophy Market Access and Reimbursement

To know more about Duchenne Muscular Dystrophy companies working in the treatment market, visit @ Duchenne Muscular Dystrophy Therapies and Drugs

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services